ATAC - Arimidex, Tamoxifen Alone or in Combination

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Anastrozole; Tamoxifen

Criteria

Inclusion Criteria:

• Patients with histologically proven operable invasive breast cancer

• Patients who have completed all primary surgery and chemotherapy (if given), and are candidates to receive hormonal adjuvant therapy

• Women defined as post-menopausal

Exclusion Criteria:

• Patients in whom there is any clinical evidence of metastatic disease

• Patients who, for whatever reason (e.g. confusion, infirmity, alcoholism), are unlikely to comply with trial requirements

• Patients whose chemotherapy was started more than 8 weeks (ie 56 days) after completion of primary surgery or whose chemotherapy was completed more than 8 weeks (ie 56 days) before starting randomised treatment